Summary: S.2967 — 114th Congress (2015-2016)All Information (Except Text)

Bill summaries are authored by CRS.

Shown Here:
Reported to Senate with amendment(s) (08/30/2016)

National Biodefense Strategy Act of 2016

(Sec. 2) This bill amends the Homeland Security Act of 2002 to direct the President to:

  • develop, submit, and periodically update a National Biodefense Strategy to direct and align federal efforts toward an effective and continuously improving biodefense enterprise, including threat awareness, prevention and protection, surveillance and detection, and response and recovery to major biological incidents;
  • establish a Biodefense Coordination Council to provide the expertise necessary to develop the strategy and which shall align government biodefense activities and spending in a manner consistent with the strategy; and
  • report annually on total federal agency expenditures on biodefense activities and how the expenditures relate to strategy goals and priorities.

The strategy shall serve as a comprehensive guide for U.S. biodefense and shall include:

  • a comprehensive description of the entities and leadership positions responsible for implementing, overseeing, and coordinating federal biodefense activities;
  • five-year goals, priorities, and metrics to improve and strengthen the government's ability to prevent, detect, respond to, and recover from a major biological incident;
  • research and development projects or initiatives planned to improve biodefense capability; and
  • recommendations for legislative action.

The strategy shall also include an appendix, which shall contain:

  • a review of collaborative efforts between the Armed Forces and the civilian sector of the government on biodefense activities and coordination; and
  • a detailed analyses of recommendations issued by external biodefense review commissions, lessons learned from the government response to public health emergencies within the preceding five years, major biological incident risks, resources and capabilities needed to address identified risks, resource and capability gaps in the biodefense enterprise, and prioritization and allocation of investment across the biodefense enterprise.